RxDoctor Payments Data

Janelle Kirby

Family · Mount Vernon, ILNPI 1942854526

Payments from drug & device makers

$5,659in general payments, 2019–2025

Across 338 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$1K
  • Madrigal Pharmaceuticals$406
  • Pfizer$377
  • Ardelyx, Inc.$318
  • Gilead$231
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,47497%
  • Education$1843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,659 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$43,316
Medicare patients
241
Services billed
452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase40$159,499
CreonLipase/Protease/Amylase12$28,043
LinzessLinaclotide19$14,141
MotegrityPrucalopride Succinate16$9,629
Lubiprostone15$1,357
Omeprazole130$1,194
Sucralfate21$1,011
Ondansetron Hcl45$1,005
Pantoprazole Sodium70$834
Famotidine52$451
Hydrocortisone14$446
Dicyclomine Hcl18$349
Lactulose18$212
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl11$210
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$98$159,49940 claims
AbbVieCreon, Linzess$1,382$42,18431 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$178$9,62916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Mount Vernon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →